Soligenix buys an orphan cancer candidate; Texas biotech backer banks $40M;

@FierceBiotech: EuroBiotech Report: AZ strikes Alderley cancer pact, Cerenis mulls IPO, 4D to start microbiome trials in 2015, more. More | Follow @FierceBiotech

@JohnCFierce: ICYMI - Merck wins breakthrough FDA approval for blockbuster cancer contender pembrolizumab. Report | Follow @JohnCFierce

@DamianFierce: $KMDA won't let a little thing like missing its endpoints in PhII/III derail a regulatory filing. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: FDA rushes J&J, NewLink Ebola vaccines to clinical trials. FierceVaccines story | Follow @EmilyMFierce

> Former SAC Capital Advisors trader Mathew Martoma, convicted of making millions in biotech's largest insider trading scheme, lost a bid to toss out his guilty verdict, setting him up for sentencing next week. News

> Soligenix paid an undisclosed sum for SGX301, a Phase III-ready treatment for an orphan form of lymphoma. More

> San Antonio biotech investor Targeted Technology has put together a $40 million fund to back emerging life sciences companies. Story

Medical Device News

@FierceMedDev: Myriad's multigene predictive cancer test shows utility in new trial. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: The metal-on-metal hip legal saga round one (of 6,000?): J&J vs. Herlihy-Paoli. Story | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery article | Follow @MichaelGFierce

@EmilyWFierce: Case hedges bets on brain device developer with a smartphone-based system for traumatic brain injuries. More from Bloomberg | Follow @EmilyWFierce

> Israeli colon capsule maker bucks M&A trend with plans for $60M IPO. News

> Researchers diagnose atrial fibrillation via webcam. Story

Pharma News

@FiercePharma: Top-read in FiercePharmaManufacturing Thursday: $ACT production not meeting demand for new version of Alzheimer's drug. Article | Follow @FiercePharma

@EricPFierce: Analysts propose hookups for troubled Wockhardt even though execs insist it is not for sale. More | Follow @EricPFierce

@CarlyHFierce: Legendary Genentech CEO Levinson cuts last ties with Roche. Story | Follow @CarlyHFierce

> Merck's melanoma 'game-changer' Keytruda likely to bolster drug pricing debate. Article

> Feds intercept pharmacist linked to meningitis outbreak as he headed to Hong Kong. Story